We have previously demonstrated that localisation of CD4+, CD8+ and CD57+ lymphocytes to sites of tumour is a requisite for the response to therapy (Donskov et al, 2002a), thus hypothesising that the antitumour activity of IFN-α in vivo is primarily cellular immune mediated. The gene discussed is CD8A; the disease is neoplasm.